Therapeutic Response

CD33 + status confers therapeutic sensitivity to Gemtuzumab ozogamicin in patients with Acute Lymphoid Leukemia.

Statements

Source and description
Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).
Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 2 years and older with relapsed or refractory CD33-positive acute myeloid leukemia (AML).